SCA Pharma

Executive Summary

SCA Pharma is a leading 503B outsourcing facility specializing in sterile compounded generic drugs, including ready-to-use medications and pre-filled syringes. The company serves hospital and healthcare facility pharmacies across the United States, with a focus on critical care, anesthesia, and pain management. Founded in 2003 and headquartered in Little Rock, Arkansas, SCA Pharma differentiates itself through a customer-centric service model, a robust product catalog, and a strong commitment to quality and reliability in the pharmaceutical supply chain. As a private company, it has not publicly disclosed funding rounds or valuation, but its position as a key supplier in the hospital pharmacy segment positions it for steady growth driven by increasing demand for outsourced sterile compounding. The company operates in a highly regulated environment under FDA oversight, which presents both risks and opportunities. The ongoing trend toward health systems outsourcing sterile compounding to mitigate contamination risks and comply with evolving USP standards favorably positions SCA Pharma. Its focus on pre-filled syringes and ready-to-use formats aligns with hospital efforts to reduce medication errors and improve efficiency. While private company financials are not available, the company's longevity and reputation suggest a stable market presence. Key risk factors include regulatory scrutiny, competition from other 503B facilities and in-house hospital pharmacies, and potential supply chain disruptions. Overall, SCA Pharma appears well-positioned in a niche but growing market, though its private status limits visibility.

Upcoming Catalysts (preview)

• Q3 2026FDA Inspection Outcome and Continued Compliance75% success
• Q4 2026Expansion of Product Line with New Ready-to-Use Formulations60% success
• Q1 2027Benefit from Updated USP <797> Standards Driving Outsourcing Demand80% success